<DOC>
	<DOC>NCT02288312</DOC>
	<brief_summary>Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects.</brief_summary>
	<brief_title>Food Effect and Dosage Form Proportionality Study of Eslicarbazepine Acetate</brief_title>
	<detailed_description>Single-centre, open-label, randomised, gender-balanced, 3-way crossover, 3-period, 3-sequence study in 18 healthy male and female subjects. The study consisted of 3 periods separated by a washout of 7 days or more between doses. Subjects received a single oral 800 mg dose of eslicarbazepine acetate following a standard meal in one period, and following at least 10 hours of fasting in two periods.</detailed_description>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male or female subjects aged between 18 and 55 years, inclusive. Subjects of body mass index (BMI, kg/m2) within the normal range [4], i.e., between 18.50 and 24.99, inclusive. Subjects who were healthy as determined by prestudy medical history, physical examination, vital signs, and 12lead ECG. Subjects who had clinical laboratory test results clinically acceptable at screening and admission to first treatment period. Subjects who had negative tests for HBsAg, antiHCVAb and anti HIV1 and HIV2 Ab at screening. Subjects who had a negative screen for alcohol and drugs of abuse at screening. Subjects who were nonsmokers or exsmokers who discontinued smoking at least 3 months prior to admission. Subjects who were able and willing to give written informed consent. (If female) She was not of childbearing potential by reason of surgery (hysterectomy or tubal ligation) or, if of childbearing potential, she used one of the following methods of contraception: intrauterine device (by the study subject) + condom (by the partner), diaphragm (by the study subject) + condom (by the partner), or spermicide (by the study subject) + condom (by the partner). (If female) She had a negative urine pregnancy test at screening and admission to each treatment period. Subjects who did not conform to the above inclusion criteria, or Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. Subjects who had a clinically relevant surgical history. Subjects who had a clinically relevant family history. Subjects who had a history of relevant drug hypersensitivity. Subjects who had a history of alcoholism or drug abuse. Subjects who consumed more than 14 units of alcohol a week. Subjects who used medicines within 2 weeks of first admission that, in the opinion of the investigator, may affect the safety or other study assessments. Subjects who used any investigational drug or participated in any clinical trial within 2 months of their first admission. Subjects who had previously received eslicarbazepine acetate (ESL, BIA 2093). Subjects who donated or received any blood or blood products within the previous 2 months prior to screening. Subjects who were vegetarians, vegans or have medical dietary restrictions. Subjects who could not communicate reliably with the investigator. Subjects who were unlikely to cooperate with the requirements of the study. Subjects who were unwilling or unable to give written informed consent. (If female) She was pregnant or breastfeeding. (If female) She was of childbearing potential and she did not used and approved effective contraceptive method or she used oral contraceptives.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>